Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report

被引：9

作者：

Li, Dan ^{[1
,2
]}

Que, Yimei ^{[1
]}

Ding, Shengnan ^{[1
,2
]}

Hu, Guang ^{[3
]}

Wang, Wen ^{[3
]}

Mao, Xia ^{[1
,2
]}

Wang, Ying ^{[1
,2
]}

Li, Chunrui ^{[1
,2
]}

Huang, Liang ^{[1
,2
]}

Zhou, Jianfeng ^{[1
,2
]}

Zhang, Wei ^{[1
,2
]}

Xiao, Min ^{[1
,2
]}

机构：

[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hematol, Wuhan, Hubei, Peoples R China

[2] Immunotherapy Res, Immunotherapy Res Ctr Hematol Dis Hubei Prov, Wuhan, Hubei, Peoples R China

[3] Nanjing IASO Biotherapeut Ltd, Nanjing, Jiangsu, Peoples R China

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷 / 09期

基金：

中国国家自然科学基金;

关键词：

PRESENILIN;

D O I：

10.1136/jitc-2022-005403

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

B cell maturation antigen (BCMA)-directed CAR-T cell therapy is a disruptive approach for treating relapsed/ refractory multiple myeloma (R/R MM); however, optimization is necessary to maximize patient benefit. We report the case of a 61-year-old woman with primary refractory MM who presented with high expression of membrane BCMA and low expression of soluble BCMA (sBCMA), experienced grade 4 cytokine release syndrome, and died fromsevere pneumonia after receiving anti-BCMA CAR-T (CT103A) therapy. This case highlights the importance of assessing the expression range of BCMA for its efficacy and safety in patients receiving BCMA CAR-T therapy. For patients who present with extremely high membrane BCMA expression and extremely low sBCMA expression, the presence of i-secretase-related gene mutations should be considered. Special attention should also be paid to the prevention and treatment of cytokine release syndrome in such patients.

引用

页数：5

共 10 条

[1] T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
Brudno, Jennifer N.
Maric, Irina
Hartman, Steven D.
Rose, Jeremy J.
Wang, Michael
Lam, Norris
Stetler-Stevenson, Maryalice
Salem, Dalia
Yuan, Constance
Pavletic, Steven
Kanakry, Jennifer A.
Ali, Syed Abbas
Mikkilineni, Lekha
Feldman, Steven A.
Stroncek, David F.
Hansen, Brenna G.
Lawrence, Judith
Patel, Rashmika
Hakim, Frances
Gress, Ronald E.
Kochenderfer, James N.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (22) : 2267 - +
[2] B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma
Cohen, Adam D.
Garfall, Alfred L.
Stadtmauer, Edward A.
Melenhorst, J. Joseph
Lacey, Simon F.
Lancaster, Eric
Vogl, Dan T.
Weiss, Brendan M.
Dengel, Karen
Nelson, Annemarie
Plesa, Gabriela
Chen, Fang
Davis, Megan M.
Hwang, Wei-Ting
Young, Regina M.
Brogdon, Jennifer L.
Isaacs, Randi
Pruteanu-Malinici, Iulian
Siegel, Don L.
Levine, Bruce L.
June, Carl H.
Milone, Michael C.
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2019, 129 (06) : 2210 - 2221
[3] Aph-1, Pen-2, and nicastrin with presenilin generate an active γ-secretase complex
De Strooper, B
[J]. NEURON, 2003, 38 (01) : 9 - 12
[4] Catabolism of endogenous and overexpressed APH1a and PEN2: evidence for artifactual involvement of the proteasome in the degradation of overexpressed proteins
Dunys, J
Kawarai, T
Wilk, S
St George-Hyslop, P
Da Costa, CA
Checler, F
[J]. BIOCHEMICAL JOURNAL, 2006, 394 : 501 - 509
[5] Understanding cytokine release syndrome
Goedel, Philipp
Shimabukuro-Vornhagen, Alexander
von Bergwelt-Baildon, Michael
[J]. INTENSIVE CARE MEDICINE, 2018, 44 (03) : 371 - 373
[6] Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Munshi, Nikhil C.
Anderson, Larry D., Jr.
Shah, Nina
Madduri, Deepu
Berdeja, Jesus
Lonial, Sagar
Raje, Noopur
Lin, Yi
Siegel, David
Oriol, Albert
Moreau, Philippe
Yakoub-Agha, Ibrahim
Delforge, Michel
Cavo, Michele
Einsele, Hermann
Goldschmidt, Hartmut
Weisel, Katja
Rambaldi, Alessandro
Reece, Donna
Petrocca, Fabio
Massaro, Monica
Connarn, Jamie N.
Kaiser, Shari
Patel, Payal
Huang, Liping
Campbell, Timothy B.
Hege, Kristen
San-Miguel, Jesus
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (08) : 705 - 716
[7] γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma
Pont, Margot J.
Hill, Tyler
Cole, Gabriel O.
Abbott, Joe J.
Kelliher, Jessica
Salter, Alexander I.
Hudecek, Michael
Comstock, Melissa L.
Rajan, Anusha
Patel, Bharvin K. R.
Voutsinas, Jenna M.
Wu, Qian
Liu, Lingfeng
Cowan, Andrew J.
Wood, Brent L.
Green, Damian J.
Riddell, Stanley R.
[J]. BLOOD, 2019, 134 (19) : 1585 - 1597
[8] Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma
Sanchez, Eric
Gillespie, Abigail
Tang, George
Ferros, Morgan
Harutyunyan, Nika Manik
Vardanyan, Suzie
Gottlieb, Jillian
Li, Mingjie
Wang, Cathy S.
Chen, Haiming
Berenson, James R.
[J]. CLINICAL CANCER RESEARCH, 2016, 22 (13) : 3383 - 3397
[9] Presenilin: Running with scissors in the membrane
Selkoe, Dennis J.
Wolfe, Michael S.
[J]. CELL, 2007, 131 (02) : 215 - 221
[10] A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma
Wang, Di
Wang, Jue
Hu, Guang
Wang, Wen
Xiao, Yi
Cai, Haodong
Jiang, Lijun
Meng, Li
Yang, Yongkun
Zhou, Xiaoxi
Hong, Zhenya
Yao, Zheng
Xiao, Min
Chen, Liting
Mao, Xia
Zhu, Li
Wang, Jin
Qiu, Lugui
Li, Chunrui
Zhou, Jianfeng
[J]. BLOOD, 2021, 137 (21) : 2890 - 2901

← 1 →